Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q4 2014 · 10-K
Revenue$598.20M$598.20M−0.7% vs Q4 2013 Net Income$39.00M$39.00M+29.6% vs Q4 2013 EPS Diluted$1.34$1.34+28.8% vs Q4 2013 Gross Profit$317,400,000−1.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
derived
Operating Cash Flowderived$40,216,000−43.0% Free Cash Flowderived$82,000−99.8% Margins · derivedGross margin53.1%−0.5 pt vs Q4 2013
Operating margin8.5%−0.2 pt vs Q4 2013
Net margin6.5%+1.5 pt vs Q4 2013
ended Dec 31, 2014 · filed Mar 2, 2015 · 61 d after period end